Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00524277 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Treating Patients With Breast Cancer
A Phase 2 study, sponsored by San Antonio Military Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 456
- Enrollment target
NCT00524277 is a Phase 2 study that has completed, run by San Antonio Military Medical Center. The registered enrollment target is 456 participants.
The verdict
NCT00524277, a Phase 2 study, has completed, sponsored by San Antonio Military Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 456 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells that express HER2/neu. Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop tumor cells from growing. It is not yet known whether vaccine therapy is more effective than GM-CSF in treating breast cancer. PURPOSE: This randomized phase II trial is studying vaccine therapy to see how well it works compared with GM-CSF in treating patients with breast cancer.
Interventions
- BIOLOGICAL GP2 peptide + GM-CSF vaccine
- BIOLOGICAL GM-CSF (sargramostim)
- BIOLOGICAL AE37 + GM-CSF vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 456 participants |
| Start Date | 2007-01 |
| Est. Completion | 2017-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00524277
The ClinicalTrials.gov registry entry for NCT00524277 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 456 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is San Antonio Military Medical Center, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which GP2 peptide + GM-CSF vaccine is the first listed.
NCT00524277 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00524277 about?
NCT00524277 is a clinical study titled "Vaccine Therapy in Treating Patients With Breast Cancer". RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells that express HER2/neu. Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop tumor cells from growing. It is not yet known whether vaccine therap...
What is the current status of trial NCT00524277?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 456 participants. The study started on 2007-01. Estimated completion is 2017-03-31.
What interventions are being tested in trial NCT00524277?
The interventions under investigation include: GP2 peptide + GM-CSF vaccine (BIOLOGICAL), GM-CSF (sargramostim) (BIOLOGICAL), AE37 + GM-CSF vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00524277?
This trial is sponsored by San Antonio Military Medical Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.